{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06329401",
            "orgStudyIdInfo": {
                "id": "AP01-007"
            },
            "organization": {
                "fullName": "Avalyn Pharma Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF",
            "therapeuticArea": [
                "Respiratory"
            ],
            "study": "a-study-evaluating-the-safety-and-efficacy-of-inhaled-in-participants-with-progressive-pulmonary-fibrosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-12",
            "studyFirstSubmitQcDate": "2024-03-19",
            "studyFirstPostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Avalyn Pharma Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "DevPro Biopharma",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.",
            "detailedDescription": "This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 (pirfenidone solution for inhalation) versus placebo on top of standard of care in participants with PPF over 52 weeks. Up to 300 eligible participants will be randomized to 1 of 3 treatment arms: AP01 high dose, AP01 low dose, or placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Progressive Pulmonary Fibrosis"
            ],
            "keywords": [
                "Chronic-Fibrosing-ILD with progressive phenotype, PF-ILD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AP01 High Dose BID",
                    "type": "EXPERIMENTAL",
                    "description": "Pirfenidone Solution for Inhalation",
                    "interventionNames": [
                        "Drug: AP01"
                    ]
                },
                {
                    "label": "AP01 Low Dose BID",
                    "type": "EXPERIMENTAL",
                    "description": "Pirfenidone Solution for Inhalation",
                    "interventionNames": [
                        "Drug: AP01"
                    ]
                },
                {
                    "label": "Placebo BID",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo solution for inhalation",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AP01",
                    "description": "Oral inhalation solution",
                    "armGroupLabels": [
                        "AP01 High Dose BID",
                        "AP01 Low Dose BID"
                    ],
                    "otherNames": [
                        "Pirfenidone Solution"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Placebo oral inhalation solution",
                    "armGroupLabels": [
                        "Placebo BID"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)",
                    "description": "Change from baseline in forced vital capacity (FVC) (mL)",
                    "timeFrame": "Week 52"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To evaluate the effect of AP01 high dose, AP01 low dose compared to placebo on quality of life (QoL)",
                    "description": "Absolute change from Baseline in QoL measurements as assessed by Living with Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) total score. The L-PF is a 44-item questionnaire to assess how impacted a participant is by disease symptoms on a scale from 0 (Not at all) to 4 (Extremely). The higher the summary score, the greater the impairment.",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To evaluate the effect of AP01 high dose and AP01 low dose compared to placebo on disease progression (defined as absolute FVC percent predicted decline of \u226510% prior to Week 52)",
                    "description": "Time to disease progression",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To evaluate the change from baseline in quantitative lung fibrosis score.",
                    "description": "Change in lung fibrosis score.",
                    "timeFrame": "52 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "To evaluate the safety of AP01 high dose and AP01 low dose compared to placebo",
                    "description": "Incidents of adverse events (AEs), serious adverse events (SAEs), and treatment-emergent deaths",
                    "timeFrame": "52 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant meets criteria for PPF, as follows:\n* In participants with ILD of known or unknown etiology other than IPF who have radiological evidence of pulmonary fibrosis, PPF is defined as:\n\nI. Physiological evidence of disease progression:\n\na. Absolute decline in FVC \u22655% predicted within the previous 6 to 12 months relative to Screening Visit 1\n\nAnd at least 1 of the following 2 criteria occurring within the past year with no alternative explanation:\n\nII. Worsening respiratory symptoms (Note: Changes attributable to comorbidities e.g., infection, heart failure must be excluded)\n\nIII. Radiological evidence of disease progression (one or more of the following):\n\na. Increased extent or severity of traction bronchiectasis and bronchiolectasis b. New ground-glass opacity with traction bronchiectasis c. New fine reticulation d. Increased extent or increased coarseness of reticular abnormality e. New or increased honeycombing f. Increased lobar volume loss\n\n* Meeting all of the following criteria during the Screening Period:\n\n  1. FVC \u226545% of predicted normal at Screening Visit 1,\n  2. Forced expiratory volume at 1 second (FEV1)/FVC \u22650.7 at Screening Visit 1,\n  3. Diffusing capacity of lung for carbon monoxide (DLCO) \u226530% of predicted, corrected for hemoglobin at Screening Visit 1,\n  4. Acceptability: Participants can perform acceptable spirometry (i.e., meet American Thoracic Society (ATS)/ European Respiratory Society (ERS) acceptability criteria at both Screening Visits).\n* For participants already on nintedanib (up to 30% of participants): Must have been on nintedanib for 6 to 12 months prior to Screening and have met criteria for PPF while on nintedanib for the same period in which the \u22655% decline in FVC was observed. Must have had no change in nintedanib dose for at least 12 weeks prior to Screening. For participants who have discontinued nintedanib prior to Screening: Must have been off of nintedanib for a minimum of 12 weeks.\n\nExclusion Criteria:\n\n* Current treatment with oral pirfenidone or treatment with oral pirfenidone within 3 months prior to Screening.\n* Elevated liver enzymes and liver injury at Screening defined as:\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u02c3 3 times the upper limit of normal (ULN)\n  2. Bilirubin \\> 1.5 x ULN\n* Renal disease with a creatinine clearance \\< 30 mL/min, calculated according to the Chronic Kidney Disease Epidemiology Collaboration formula. Retesting is allowed once.\n* Diagnosis of idiopathic pulmonary fibrosis (IPF) based on the ATS diagnostic algorithm for IPF. UIP that is not idiopathic, for example related to rheumatoid arthritis (RA), familial interstitial lung disease (ILD), or other is not exclusionary.\n* Greater extent of emphysema than of fibrotic ILD on HRCT. Note: CT results must be confirmed through the central over read process.\n* Significant clinical worsening of PPF between Screening\n* Participants who cannot meet protocol-specified Baseline stability criteria. FVC Baseline stability is defined as the FVC assessments at Visit 3 being within \u00b112% of the mean of the FVC assessments obtained at the 2 preceding visits. At Visit 3, if the pre-dose FVC is outside of \u00b112% range, the participant will not be randomized and will be considered a screen failure.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Craig S. Conoscenti, MD",
                    "role": "CONTACT",
                    "phone": "206-707-0304",
                    "email": "cconoscenti@avalynpharma.com"
                },
                {
                    "name": "Daniele Tompkins",
                    "role": "CONTACT",
                    "phone": "973-983-3700",
                    "phoneExt": "205",
                    "email": "dtompkins@devprobiopharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Avalyn Pharma, Inc.",
                    "affiliation": "Avalyn Pharma Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Newport Native MD, Inc.",
                    "status": "RECRUITING",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "Paradigm Clinical Research - Redding",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Redding",
                    "state": "California",
                    "zip": "96001",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.58654,
                        "lon": -122.39168
                    }
                },
                {
                    "facility": "Clinical Site Partners, LCC",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Leesburg",
                    "state": "Florida",
                    "zip": "34748",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.81082,
                        "lon": -81.87786
                    }
                },
                {
                    "facility": "Renstar Medical Research",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Ocala",
                    "state": "Florida",
                    "zip": "34470",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.1872,
                        "lon": -82.14009
                    }
                },
                {
                    "facility": "Clinical Site Partners",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Winter Park",
                    "state": "Florida",
                    "zip": "32789",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.6,
                        "lon": -81.33924
                    }
                },
                {
                    "facility": "Accellacare",
                    "status": "RECRUITING",
                    "city": "Wilmington",
                    "state": "North Carolina",
                    "zip": "28401",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.22573,
                        "lon": -77.94471
                    }
                },
                {
                    "facility": "Southeastern Research Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                },
                {
                    "facility": "Lowcountry Lung and Critical Care",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29406",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "36948586",
                    "type": "RESULT",
                    "citation": "West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, Corte TJ, Sterclova M, Veale A, Jassem E, Wijsenbeek MS, Grainge C, Piotrowski W, Raghu G, Shaffer ML, Nair D, Freeman L, Otto K, Montgomery AB. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023 Sep;78(9):882-889. doi: 10.1136/thorax-2022-219391. Epub 2023 Mar 22."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Content",
                    "url": "http://thorax.bmj.com/content/78/9/882.long"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011658",
                    "term": "Pulmonary Fibrosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000017563",
                    "term": "Lung Diseases, Interstitial"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14512",
                    "name": "Pulmonary Fibrosis",
                    "asFound": "Pulmonary Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27137",
                    "name": "Respiratory Aspiration",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19813",
                    "name": "Lung Diseases, Interstitial",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000093844",
                    "term": "Pirfenidone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000894",
                    "term": "Anti-Inflammatory Agents, Non-Steroidal"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M194811",
                    "name": "Pirfenidone",
                    "asFound": "Mediterranean diet",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4218",
                    "name": "Anti-Inflammatory Agents, Non-Steroidal",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}